About us
Founded in 2000 in Grenoble, France, PX'Therapeutics (formerly known as Protein'eXpert) has been offering contract research services focusing on the engineering and development of valuable and complex recombinant proteins. PX'Therapeutics has then extended its range of services to the biomanufacturing of therapeutic protein products for early clinical trials via its integrated subsidiary PX'Pharma in 2004. PX'Pharma has been providing dedicated contract services for process development & scale-up optimization, preclinical and clinical GMP production. In 2007, a new subsidiary named PX'Monoclonals was created to propose services ranging from the generation of high affinity murine monoclonal antibodies to the development of chimeric and humanized antibodies for therapeutic use. On September 2008, Protein'eXpert became PX'Therapeutics.
This change of name reflects the company’s strategy to accompany biotech and pharma clients all along the development of their biotherapeutic candidates with a mission to optimize timelines and bring value to their pipeline. The combination of protein expertise and manufacturing capabilities of the PX’Therapeutics group ensures a seamless transfer from the discovery stage up to clinical
• 2000 Creation
of Protein’eXpert, CRO devoted to the engineering, development and production
of valuable recombinant proteins
• 2004 Set up of the subsidiary PX’Pharma offering GMP clinical manufacturing services
• 2007 Set up of the subsidiary PX’Monoclonals in Lyon dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes
• 2008 Signature of a co-commercialization agreement with the company Althea Technologies (San Diego, USA)
• 2008 Protein’eXpert changes name to PX’Therapeutics in order to highlight its focus on integrated biotherapeutics development
• 2010 (Q3) Creation of a new subsidiary PROMISE Advanced Proteomics offering unique protein Absolute Quantification services
• 2010 (Q4) Opening of new GMP mammalian cell culture manufacturing facility
• 2004 Set up of the subsidiary PX’Pharma offering GMP clinical manufacturing services
• 2007 Set up of the subsidiary PX’Monoclonals in Lyon dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes
• 2008 Signature of a co-commercialization agreement with the company Althea Technologies (San Diego, USA)
• 2008 Protein’eXpert changes name to PX’Therapeutics in order to highlight its focus on integrated biotherapeutics development
• 2010 (Q3) Creation of a new subsidiary PROMISE Advanced Proteomics offering unique protein Absolute Quantification services
• 2010 (Q4) Opening of new GMP mammalian cell culture manufacturing facility
manufacturing steps for complex
biotherapeutic projects (therapeutic proteins, recombinant vaccines and
monoclonal antibodies).
In August 2010, PX’Therapeutics offers new services for absolute quantification of proteins based on PSAQ™ method through a new subsidiary PROMISE Advanced Proteomics, a spin-off company from the “Exploring the Dynamics of Proteomes” laboratory (CEA/INSERM/UJF).
A new GMP mammalian cell culture facility has also been approved in 2010 and has opened to clients and partners.
In August 2010, PX’Therapeutics offers new services for absolute quantification of proteins based on PSAQ™ method through a new subsidiary PROMISE Advanced Proteomics, a spin-off company from the “Exploring the Dynamics of Proteomes” laboratory (CEA/INSERM/UJF).
A new GMP mammalian cell culture facility has also been approved in 2010 and has opened to clients and partners.